



# WISELY ORDERING RHEUMATOLOGIC ANTIBODIES

Benjamin Wang, M.D., FRCPC  
Division of Rheumatology  
Mayo Clinic  
Jacksonville, FL

Baptist Health South Florida  
Boca Raton Regional Hospital  
Annual Internal Medicine Conference  
March 22-24, 2024

©2024 Mayo Foundation for Medical Education and Research | slide-1

1

## DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S) WITH INELIGIBLE COMPANIES

**Benjamin Wang, M.D.**, faculty for this educational activity, has no relevant financial relationships with ineligible companies to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.

©2024 Mayo Foundation for Medical Education and Research | slide-2

2



**“PROBLEMS  
WORTHY OF  
ATTACK  
PROVE THEIR  
WORTH BY  
FIGHTING BACK.”**  
— PIET HEIN

Image copyright Gettyimages  
©2024 Mayo Foundation for Medical Education and Research | slide-3


3

## **LEARNING OBJECTIVE**

- To recognize broad categories of autoimmune antibodies used in diagnosing rheumatic diseases
- To learn the correlation of certain autoantibodies with specific clinical manifestations
- To utilize rheumatology immunologic testing to confirm the diagnosis of autoimmune syndromes

©2024 Mayo Foundation for Medical Education and Research | slide-4

4




## OVERVIEW

- Autoantibodies and Disease: clinical strategy
- Associations with specific syndromes
  - SLE and neonatal lupus
  - Other systemic autoimmune diseases
  - Rheumatoid arthritis
  - Myositis
  - Vasculitis and ANCA-associated syndromes
- Case study

©2024 Mayo Foundation for Medical Education and Research | slide-5

5



## CLINICAL PROBLEM SOLVING IS A PUZZLE WITH MISSING PIECES DERIVED FROM MULTIPLE SOURCES

- **Clinical evaluation**
  - Symptoms
  - Signs
- **Laboratory testing**
  - Organ function
  - Inflammation
  - Immunology
- **Diagnostic testing**
  - Imaging
  - Functional testing
  - Histologic examination
- **Pattern recognition**

©2024 Mayo Foundation for Medical Education and Research | slide-6

6

## STANDARD OPERATING PRINCIPLES

- **Be clinically based**  
Confirm diagnoses based on what you see and hear
- **Be hypothesis-driven**  
Avoid “fishing expeditions” which can mislead
- **Be aware that disease classification has limitations**  
Many cases will not fit cleanly into established definitions
- **Diagnostic tests add to clinical observations, not replace them**  
No test is absolute or perfect (is RF a test for rheumatoid arthritis? How specific a test is it?)



7

## ANTIBODIES IN THE SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASE (SARD) GROUP

ANA PROFILES IN ANA-POSITIVE RHEUMATIC DISEASE							
ANTIBODY SPECIFICITY	ACTIVE SLE	MCTD	PSS	CREST	PRIMARY SJOGREN'S	RA	DRUG-INDUCED SLE
ANA	>95%	>95%	70-90%	60-90%	>70%	40-50%	100%
Anti-dsDNA	60%	Negative	Negative	Negative	Rare	Rare	Negative
Anti-Sm	30%	Negative	Negative	Negative	Negative	Negative	Negative
Anti-RNP	30%	>95% (high titer)	Common (low titer)	Negative	Rare (low titer)	Rare	10-20% (low titer)
Anti-Centromere	Rare	Rare	10-15%	60-90%	Negative	Negative	Negative
Anti-Ro (SS-A)	30%	Rare	Rare	Negative	70%	10-15%	Negative
Anti-La (SS-B)	15%	Rare	Rare	Negative	60%	Rare	Negative
Anti-Nucleolar	Occasional	Negative	Common	Negative	Occasional	Rare	Negative
Anti-Sci-70	Rare	Negative	10-20%	Negative	Negative	Negative	Negative
Anti-Histone	24-95%	Occasional	Occasional	Occasional	Occasional	20%	Procainamide: 67-100% Sensitivity Hydralazine: 50-100% Sensitivity

Abbreviations: SLE – systemic lupus erythematosus; MCTD – mixed connective tissue disease; PSS – progressive systemic sclerosis (here meaning diffuse scleroderma); CREST – calcinosis, Raynaud’s, esophageal dysmotility, sclerodactyly, telangiectasia (here meaning limited scleroderma); RA – rheumatoid arthritis

Morris, R. RDL Laboratories, Inc. Los Angeles, CA

©2024 Mayo Foundation for Medical Education and Research | slide-8

8

## CLINICAL SYMPTOMS OR SIGNS MAY RAISE CLINICAL SUSPICION FOR AUTOIMMUNE DISEASES

	Higher Suspicion (specific)	Lower Suspicion (non-specific)
<b>Arthritis</b>	Specific swollen joints or tendons on exam	Joint pain without swelling or prolonged AM stiffness (<30')
<b>Rash</b>	Objective inflammatory rash	Transient rashes
<b>Sicca</b>	Sipping water constantly, dental issues, corneal abrasion	Non-severe dry eyes, dry mouth
<b>Raynaud's</b>	At least bluish discoloration on cold exposure, tri-color changes	Pain with cold exposure, no color change
<b>Photosensitivity</b>	Objective photosensitive rash	Fatigue after sun exposure
<b>Alopecia</b>	Patchy, moth eaten hair loss	Generalized hair loss, receding hairline, androgenic pattern
<b>Renal</b>	Decreased function, heavy proteinuria, inflammatory casts, edema	Stable renal function, trace/1+ proteinuria, edema, flank pain, recurrent UTIs
<b>Serositis</b>	Documented pericarditis, pleuritis	Nonspecific chest pain

©2024 Mayo Foundation for Medical Education and Research | slide-9

9

## GENERAL CORRELATIONS BETWEEN CLINICAL FEATURES AND SPECIFIC ANTIBODIES

CLINICAL MANIFESTATION	SEROLOGIC TEST
<b>Skin, joint, mucous membrane</b>	anti-SSA, SSB
<b>Nephritis</b>	anti-dsDNA, anti-chromatin, anti-Smith, low C3 / C4
<b>Sclerodactyly (skin thickening)</b>	anti-centromere, anti-Scl70, anti-RNP, anti-RNA polymerase III
<b>Raynaud's</b>	anti-centromere, anti-Scl70, anti-RNP, anti-RNA polymerase III
<b>Thrombosis, pregnancy loss</b>	antiphospholipid, anti- $\beta_2$ glycoprotein I, lupus anticoagulant
<b>Cytopenias</b>	dsDNA, Smith,
<b>Interstitial lung disease</b>	RF, ANA, anti-Jo-1, myositis-related antibodies
<b>Neonatal lupus</b>	anti-SSA, anti-SSB

©2024 Mayo Foundation for Medical Education and Research | slide-10

10

## ORDERING ANTIBODY TESTS ACCORDING TO THE CLINICAL PICTURE

	HIGHER SUSPICION (SPECIFIC)	LOWER SUSPICION (NON-SPECIFIC)	APPROPRIATE ANTIBODIES
<b>Arthritis</b>	Specific swollen joints or tendons on exam	Joint pain without swelling or prolonged AM stiffness (<30')	RF, CCP ANA, SSA, SSB, dsDNA
<b>Rash</b>	Objective inflammatory rash	Transient rashes	ANA, SSA, SSB
<b>Sicca</b>	Sipping water constantly, dental issues, corneal abrasion	Non-severe dry eyes, dry mouth	ANA, SSA, SSB Mitochondrial
<b>Raynaud's or skin thickening or esophageal</b>	At least bluish discoloration on cold exposure, tri-color changes; distal skin thickened	Pain with cold exposure, no color change	ANA, RNP, Scl-70, centromere, RNA pol III Myositis-related Abs
<b>Photosensitivity</b>	Objective photosensitive rash	Fatigue after sun exposure	SSA, SSB
<b>Alopecia</b>	Patchy, moth eaten hair loss	Generalized hair loss, receding hairline, androgenic pattern	ANA, SSA, SSB dsDNA, centromere, Scl-70
<b>Renal</b>	Decreased function, heavy proteinuria, inflammatory casts	Stable renal function, trace/1+ proteinuria, edema, flank pain, recurrent UTIs	ANA, dsDNA, Smith C3, C4
<b>Serositis</b>	Documented pericarditis, pleuritis	Nonspecific chest pain	ANA, SSA, SSB, dsDNA

©2024 Mayo Foundation for Medical Education and Research | slide-11

11

## SYSTEMIC LUPUS – SOME FINE POINTS

- **Lupus tends to segregate into subsets:**
  - Milder disease, mostly skin, joint involvement: SSA, SSB (+)
  - Severe disease, visceral involvement: Strong ANA, anti-dsDNA, -RNP, C3 low, C4 low
  - Clinically quiescent-serologically active lupus
  - Risk of having lupus with a negative ANA: almost zero (0.14 percent). If anything, these may be anti-SSA/B positive (test if clinically suspect)
- **What is the Extractable Nuclear Antigen (ENA) panel?**
  - Anti-SSA, -SSB
  - Anti-Smith, RNP
  - Anti-Scl70, Jo-1
- **Which antibodies are correlated with disease activity?**
  - ANA is not reliable – up to 1:160 is borderline; Mayo Lab ELISA: 1.1 - 2.9 Units (Weakly Positive)
  - dsDNA antibody and C3, C4 probably best, but changes often occur before clinical manifestations are apparent

©2024 Mayo Foundation for Medical Education and Research | slide-12

12

## MORE AUTOANTIBODY-DISEASE CORRELATION

- **Scleroderma**
  - Centromere Ab: 30% of limited scleroderma
  - Scl70 antibody: 30% of diffuse scleroderma
- **Mixed connective tissue disease (MCTD)**
  - anti-RNP positive, PUFFY HANDS, Raynaud's phenomenon
- **Overlap syndromes**
  - two or more concomitant autoimmune diseases; mainly a clinical diagnosis, no standard antibody pattern
  - RA-SLE ("Rhus") (note: Sjogren's syndrome may be positive for ANA, RF, SSA, SSB, and CCP)
- **Undifferentiated connective tissue disease**
  - "Incomplete Lupus," "Lupus that doesn't check all the boxes"

©2024 Mayo Foundation for Medical Education and Research | slide-13

13

## RHEUMATOID ARTHRITIS

- Rheumatoid factor
- Anti-cyclic citrullinated peptide antibody (CCP)

©2024 Mayo Foundation for Medical Education and Research | slide-14

14

## SPONDYLOARTHRITIS

- Negative serology for lupus and other SARDs
- HLA-B27 is the only diagnostic lab marker
  - This allele occurs in 8% of general U.S. population
  - In a patient with typical symptoms, its presence increases the likelihood of true disease to over 95%
- Key Clinical Features
  - Inflammatory back pain
  - Peripheral oligoarthritis (often large joint)
  - Inflammatory skin, ocular (uveitis) or bowel disease
  - Psoriasis

©2024 Mayo Foundation for Medical Education and Research | slide-15

15

## MYOSITIS

- Inflammatory, autoimmune myositis such as polymyositis and dermatomyositis may have associated autoantibodies that have prognostic value:
  - Anti-Jo-1: interstitial lung disease, Raynaud's phenomenon, arthritis, and mechanic's hands
  - Anti-Mi2: acute onset of classic DM with erythroderma and the shawl sign
  - Anti-SRP: severe myopathy and aggressive disease



©2024 Mayo Foundation for Medical Education and Research | slide-16

16



### Myositis-Specific Abs, Myositis-Associated Abs and Their Clinical Associations

Antibody	Myositis-Specific Abs	Myositis-Associated Abs	PM	DM	Anti-Synthetase Syndrome	Overlap Syndrome	Myositis (Juvenile)	ILD	Arthritis
<b>Mi-2*</b>	4-14%	Not Applicable	Rare	Common	Not Applicable	Common	10%	Rare	Occas
<b>SRP*</b>	4%	Not Applicable	Common	Occas	Not Applicable	Not Described	Uncommon	Common	Common
<b>Jo-1*</b>	20%	Not Applicable	Common	Occas	Marker	Common	Reported	Common	Common
PL-7	1-4%	Not Applicable	Occas	Common	Marker	Common	Reported	Common	Common
PL-12	1-4%	Not Applicable	Occas	Common	Marker	Common	Reported	Common	Common
OJ	1-4%	Not Applicable	Occas	Common	Marker	Common	Reported	Common	Common
EJ	1-4%	Not Applicable	Occas	Common	Marker	Common	Reported	Common	Common
PM/Scl	Not Applicable	8%	Uncommon	Uncommon	Not Applicable	Common	Occas	Rare	Common
Ku	Not Applicable	% Unknown	Not Described	Not Described	Not Applicable	Common	Occas	Not Described	% Unknown
U2 snRNP	Not Applicable	% Unknown	Not Described	Not Described	Not Applicable	Common	Not Described	Not Described	% Unknown

Note: this is very esoteric and not always clinically necessary in primary care


Morris, R. RDL Laboratories, Inc. Los Angeles, CA

©2024 Mayo Foundation for Medical Education and Research | slide-17

17

## VASCULITIS AND ANCA-ASSOCIATED SYNDROMES

- c-ANCA and p-ANCA are positive in a limited number of systemic vasculitides
- They are associated with certain finer specific antigens
  - c-ANCA – proteinase 3 (PR3)
  - P-ANCA – myeloperoxidase (MPO), lactoferrin, and other non-MPO antigens
- When c-ANCA and p-ANCA are positive but PR3 and MPO are negative, this may point to the presence of and “atypical ANCA,” which are often seen in inflammatory bowel disease



©2024 Mayo Foundation for Medical Education and Research | slide-18

18

FREQUENCY OF C-ANCA, P-ANCA, MPO & PR-3 ABS IN VASCULITIS				
DISEASE CATEGORY	C-ANCA	P-ANCA	ANTI-MPO	ANTI-PR3
WEGENER'S GRANULOMATOSIS Active - generalized Active - limited	3-4+ 2-3+	1+ Occasionally	1+ <1+	3-4+ 2-3+
Idiopathic Necrotizing and Crescentic Glomerulonephritis without Immune deposits (Pauci-Immune)	Rare	4+	3-4+	Rare
Microscopic Polyarteritis	1+	2-3+	2-3+	1+
Churg-Strauss Syndrome	1+	2+	2+	1+
Classic Polyarteritis Nodosa Polyangitis Overlap Syndrome	Rare 1+	Rare 1+	Rare 1+	Rare Rare
INFLAMMATORY BOWEL DISEASE Ulcerative Colitis Crohn's Disease	Absent Absent	2-4+ 1+	Absent Absent	Absent Absent
GRADING SYSTEM: 1+(15-25%); 2+(26-50%); 3+(51-75%); 4+(76-100%)				

Morris, R. RDL Laboratories, Inc. Los Angeles, CA

©2024 Mayo Foundation for Medical Education and Research | slide-19

19

## CLINICAL CASE

A 68-year-old woman presents with severe dryness of the eyes and mouth. A review of medications does not disclose any strongly implicated drugs that may be causing this.

She also complains of joint pain with swelling involving her hands and wrists.

Physical examination is remarkable for a mild left foot drop and pinprick sensory deficit along the left L5 dermatome. Her mucous membranes are severely dry, and several dental caries are seen. She has a faint bilateral conjunctival injection. There is mild synovitis of the right wrist and 2 MCP joints of each of the right and left hand. There is no palpable lymphadenopathy.

*Considering that she may have a systemic autoimmune disorder, what would your diagnostic approach be?*


- Consider the possibility of systemic lupus: obtain ANA, dsDNA, ENA panel (SSA, SSB, RNP, Smith)
- Consider the possibility of primary Sjogren's Syndrome: SSA, SSB, ANA, RF
- This may be RA with secondary Sjogren's: RF, CCP
- All of the above may apply – test all of the above antibodies



20

## CONCLUSION

- The immunology lab can be powerful to define diseases but is often a source of confusion
- The lab must be applied with knowledge of the clinical scenario, understanding what the clinical likelihood of disease is; the lab tests are used to confirm or refute the clinical suspicion
- Knowing the range of antibody tests, the symptoms and signs of autoimmune diseases, and the associations between the two will aid pattern recognition to arrive at the diagnosis of these syndromes



21

## QUESTIONS & ANSWERS



©2024 Mayo Foundation for Medical Education and Research | slide-22

22